2022
DOI: 10.1096/fj.202101492r
|View full text |Cite
|
Sign up to set email alerts
|

Population differences in antibody response to SARS‐CoV‐2 infection and BNT162b2 vaccination

Abstract: The concentration of SARS‐CoV‐2‐specific serum antibodies, elicited by vaccination or infection, is a primary determinant of anti‐viral immunity, which correlates with protection against infection and COVID‐19. Serum samples were obtained from 25 897 participants and assayed for anti‐SARS‐CoV‐2 spike protein RBD IgG antibodies. The cohort was composed of newly vaccinated BNT162b2 recipients, in the first month or 6 months after vaccination, COVID‐19 patients and a general sample of the Israeli population. Anti… Show more

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

2
6
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
6
2

Relationship

2
6

Authors

Journals

citations
Cited by 10 publications
(8 citation statements)
references
References 50 publications
2
6
0
Order By: Relevance
“…In line with our results, lower S-antibody levels shortly after vaccination among those of higher age or with medical conditions have been reported for the primary series (2-5, 15, 16). Also, Sanada et al .…”
Section: Discussionsupporting
confidence: 92%
“…In line with our results, lower S-antibody levels shortly after vaccination among those of higher age or with medical conditions have been reported for the primary series (2-5, 15, 16). Also, Sanada et al .…”
Section: Discussionsupporting
confidence: 92%
“…Long‐term immunomodulatory effects of IVIg, like induction of inhibitory Fc gamma receptors on B cells [14], or, as observed in a recent study on rheumatic diseases and COVID‐19 vaccination [27], altered efficacy of the immune system due to autoimmunity, could generally explain our finding that anti‐SARS‐CoV‐2 IgG serum titers remained lower in immune neuropathy patients than in age‐matched healthy subjects after the second COVID‐19 vaccine dose. Furthermore, sex‐related differences in anti‐SARS‐CoV‐2 IgG generation have to be considered a confounding factor, possibly exaggerating the difference between immune neuropathy patients (25% female) and healthy subjects (83% female), as a recent study demonstrated that female sex is associated with higher anti‐SARS‐CoV‐2 antibody titers after COVID‐19 mRNA vaccination [28]. However, all patients showed anti‐SARS‐CoV‐2 IgG titers far above the cutoff for positivity and most within the range of healthy subjects without significant difference compared to healthy subjects at follow‐up.…”
Section: Discussionmentioning
confidence: 99%
“…Anti-SARS-CoV-2 IgM titers in patients with immune neuropathies and healthy subjects female) and healthy subjects (83% female), as a recent study demonstrated that female sex is associated with higher anti-SARS-CoV-2 antibody titers after COVID-19 mRNA vaccination [28]. However, all patients showed anti-SARS-CoV-2 IgG titers far above the cutoff for positivity and most within the range of healthy subjects without significant difference compared to healthy subjects at follow-up.…”
Section: Ta B L Ementioning
confidence: 93%
“…Consistent with our findings, increased antibody responses to various vaccines in females have been previously reported. 85 , 86 , 87 , 88 …”
Section: Discussionmentioning
confidence: 99%